Nab-paclitaxel in Metastatic Breast Cancer Patients Failing Solvent Based Taxane (Tiffany)

This study has been terminated.
(Study was terminated because of extrem low recruitment)
Sponsor:
Information provided by (Responsible Party):
German Breast Group
ClinicalTrials.gov Identifier:
NCT01416558
First received: August 11, 2011
Last updated: May 21, 2013
Last verified: May 2013
  Purpose

Nab-paclitaxel has demonstrated to be an active agent in breast cancer and probably a less toxic alternative to solvent based taxanes. It is indicated in metastatic breast cancer after failure of anthracyclines. However, most patients receive anthracyclines as well as taxanes as part of their (neo-)adjuvant therapy. There is currently no standard treatment for patients with an early relapse (<12 months) after a taxane containing (neo-)adjuvant therapy. Nab-paclitaxel, a novel nano-particle encapsulated paclitaxel is expected to have only limited cross-resistant to solvent-based taxanes and might therefore be indicated in this setting.


Condition Intervention Phase
Metastatic Breast Cancer
Drug: Nab-Paclitaxel
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter Non-randomized Phase II Study to Evaluate Nab-paclitaxel in Metastatic Brest Cancer Patients Failing a Solvent Based Taxane as (Neo-)Adjuvant Treatment (Tiffany)

Resource links provided by NLM:


Further study details as provided by German Breast Group:

Primary Outcome Measures:
  • Overall response rate (ORR) [ Time Frame: 3 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Toxicity of the therapy [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
    Number and percent of patients with Adverse Events (any Grade and Grade 3/4).

  • Clinical benefit rate (CBR) in patients with measurable disease [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Duration of response [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Progression-free survival (PFS) [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Overall survival (OS) [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • SPARC expression rate of the tissue of the primary and/or metastatic tumor [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Compliance of the therapy [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
    Number and percent of the patients with treatment modifications (dose delay / dose reduction / premature dicontinuation)


Estimated Enrollment: 66
Study Start Date: July 2011
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Nab-Paclitaxel

    Nab-Paclitaxel 125 mg/m2 i.v. over 30 min. weekly in 5 out of 6 weeks

    Given until progression, unacceptable toxicity, patient's request or withdrawal from Study

    Other Name: Abraxane, EU/1/07/428/001
Detailed Description:

Primary Objective:

To determine overall response rate (ORR) and to exclude that it is 20% or lower.

Secondary Objectives:

  1. To determine compliance and toxicity of the therapy.
  2. To determine clinical benefit rate (CBR) in patients with measurable disease.
  3. To determine duration of response.
  4. To determine progression-free survival (PFS).
  5. To determine overall survival.
  6. To assess biomarkers, e.g. SPARC expression in the tissue of the primary or metastatic tumor.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent for all study procedures according to local regulatory requirements prior to beginning specific protocol procedures.
  • Complete baseline documentation must be submitted via the web-based data collection system MedCODES to the GBG Forschungs GmbH.
  • Diagnosis of locally advanced or metastatic hormone-sensitive or insensitive, HER2-negative or -positive breast cancer.
  • Relapse within ≤ 12 months after completing (last day of last cycle) (neo-) adjuvant chemotherapy.
  • Documented relapse of either a measurable or a non-measurable lesion according to the modified RECIST criteria.
  • Previous neoadjuvant or adjuvant treatment with a solvent based taxane (paclitaxel or docetaxel) irrespective of dose and duration.
  • Prior endocrine treatment for metastatic / advanced disease is allowed.
  • Complete radiological and clinical tumor assessment within 4 weeks prior to registration performed as clinically indicated.
  • Age ≥ 18 years.
  • ECOG Performance Status ≤ 2 (irrespective of restrictions due to breast cancer).
  • Laboratory requirements:Absolute neutrophil count (ANC) >= 1.5 x 109/L., Platelets >= 100 x 109/L., Hemoglobin >= 9 g/dL (>= 5.6 mmol/L)., Prothrombin time (PT) or international normalized ratio (INR) <= 1.2x ULN (upper normal limit), Partial thromboplastin time (PTT) <= 1.2x ULN, Total bilirubin < 1.5x ULN, ASAT (SGOT) and ALAT (SGPT) <= 2.5x ULN (concomitant elevations in serum bilirubin and ASAT/ALAT above 1.0x ULN are not permitted), Creatinine clearance >= 50 mL/min), Urine Protein to Creatinine Ratio (UPC) < 1 (if UPC >= 1, then 24-hour urine protein must be < 1 g).
  • Normal cardiac function confirmed by ECG.
  • A female either of: 1) Non-childbearing potential, i.e. physiologically incapable of becoming pregnant because of history of hysterectomy, bilateral oophorectomy (ovariectomy), bilateral tubal ligation or postmenopausal status.

    2) Childbearing potential with a negative pregnancy test (urine or serum)within 2 weeks prior to registration, preferably as close to the first dose as possible, and agrees to use adequate contraception.

Acceptable contraceptive methods, when used consistently and in accordance with both the product label and the instructions of the physician, are as follows:

An intrauterine device with a documented failure rate of less than 1% per year, Vasectomised partner who is sterile prior to the female subject's entry and is the sole sexual partner for that female, Complete abstinence from sexual intercourse for 14 days before exposure to the investigational product, through the dosing period, and for at least 21 days after the last dose of investigational product, Double-barrier contraception (condom with spermicidal jelly, foam suppository, or film; diaphragm with spermicide; or male condom and diaphragm with spermicide).

  • Female subjects who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for 14 days following the last dose of study drug.

Exclusion Criteria:

  • Known or suspected hypersensitivity reaction to the investigational compounds or incorporated substances.
  • (Neo-)adjuvant therapy not containing a solvent based taxane.
  • (Neo-)adjuvant therapy with nab-paclitaxel.
  • Concurrent hormonal therapy for cancer.
  • Life expectancy less than 3 months.
  • Pre-existing peripheral neuropathy of > grade 2 (per CTCAE).
  • Pre-existing grade 3 or 4 diarrhea.
  • Presence of uncontrolled infection.
  • Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with the subject's safety, provision of informed consent, or compliance to study procedures.
  • Concurrent specific systemic anti-tumor treatment or treatment with experimental compounds during study treatment.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01416558

Locations
Germany
GBG Forschungs GmbH
Neu-Isenburg, Germany, 63263
Sponsors and Collaborators
German Breast Group
  More Information

Additional Information:
No publications provided

Responsible Party: German Breast Group
ClinicalTrials.gov Identifier: NCT01416558     History of Changes
Other Study ID Numbers: GBG 65, 2011-000075-13
Study First Received: August 11, 2011
Last Updated: May 21, 2013
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by German Breast Group:
German Breast Group
GBG Forschungs GmbH
GBG
GBG 65
Tiffany
Breast Cancer
Metastatic Breast Cancer
Nab-Paclitaxel
Abraxane
Taxane Failure

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Paclitaxel
Taxane
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on April 23, 2014